Results 171 to 180 of about 82,006 (284)

Combined Inhibition of TRPM4/NMDA Receptor Complex and Extrasynaptic NMDA Receptors Is Candidate Therapeutic Target for Suppression of Epileptic Seizures and Improvement of Cognitive Impairments

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Cognitive impairments are important therapeutic targets in epilepsy medication; however, effective pharmacological treatments for epilepsy patients with comorbid cognitive impairment have not been established. Effects of chronic administration of MK‐801 (noncompetitive NMDA receptor inhibitor), memantine (low‐affinity extrasynaptic‐NMDA ...
Motohiro Okada   +3 more
wiley   +1 more source

Prevalence of Potentially Inappropriate Apixaban Prescribing Within a Single‐Centre Tertiary Hospital

open access: yesAustralasian Journal on Ageing, Volume 45, Issue 2, June 2026.
ABSTRACT Objective Apixaban is widely recommended as first line therapy for atrial fibrillation (AF) and venous thromboembolism (VTE). Despite the widespread availability of dosing guidelines, anecdotal evidence suggests clinicians do not routinely follow these recommendations. Inappropriate dose reduction is associated with suboptimal patient outcomes.
Katherine J. Creeper   +5 more
wiley   +1 more source

Epicutaneous and Drug Provocation Testing in Severe Cutaneous Adverse Reactions: A 20‐Year Single‐Centre Experience

open access: yesContact Dermatitis, Volume 94, Issue 6, Page 677-688, June 2026.
This study provides reassuring evidence in favour of early skin testing in patients with SCARs, argues against the necessity of a 6‐month delay, and underscores the pivotal role of oral provocation tests in the safe reintroduction of essential therapies. ABSTRACT Background Identifying and discontinuing the offending drug(s) in severe cutaneous adverse
Zohra Chadli   +8 more
wiley   +1 more source

Dissolved Organic Matter and Pretreatment Effects on PFAS Removal by Granular Activated Carbon

open access: yesAWWA Water Science, Volume 8, Issue 3, May/June 2026.
ABSTRACT Granular activated carbon (GAC) adsorption is commonly used to remove per‐ and polyfluoroalkyl substances (PFAS) from water. In this study, we evaluated the impact of dissolved organic matter (DOM) concentration and pretreatment on GAC use rates for PFAS removal.
Tiffany Tang   +2 more
wiley   +1 more source

Epilepsy in Chinese Children With Mowat–Wilson Syndrome: Two Case Reports and Literature Review

open access: yes
Journal of Paediatrics and Child Health, EarlyView.
Xuelin Huang   +6 more
wiley   +1 more source

Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1287-1308, May 2026.
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou   +2 more
wiley   +1 more source

Lingual Dyskinesia as the Presenting Feature of Acquired Demyelinating Syndrome: A Case Report and Review of Differential Diagnoses

open access: yes
Journal of Paediatrics and Child Health, EarlyView.
Briana Davis   +3 more
wiley   +1 more source

Systematic Management of a Critical CYP3A4 Interaction Between Cabozantinib and Carbamazepine: A Case Report of a Clinically Relevant Pharmacokinetic Interaction

open access: yesClinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT This was the case of a 62‐year‐old patient treated with cabozantinib and nivolumab for metastatic clear cell renal cell carcinoma, in whom a clinically significant pharmacokinetic interaction with carbamazepine was observed. Carbamazepine, a potent inducer of CYP3A4, caused a major decrease in systemic exposure to cabozantinib, as confirmed by
Pierre Nizet   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy